MindMed als Marktführer einer neuen Multimilliarden-Anlageklasse (Seite 20)
eröffnet am 10.03.20 10:27:59 von
neuester Beitrag 05.04.24 22:18:33 von
neuester Beitrag 05.04.24 22:18:33 von
Beiträge: 274
ID: 1.321.613
ID: 1.321.613
Aufrufe heute: 3
Gesamt: 45.287
Gesamt: 45.287
Aktive User: 0
ISIN: CA60255C8850 · WKN: A3DR6E · Symbol: MNMD
9,3600
USD
-0,74 %
-0,0700 USD
Letzter Kurs 18:01:41 Nasdaq
Neuigkeiten
13:00 Uhr · Business Wire (engl.)  |
25.04.24 · Business Wire (engl.) |
15.04.24 · Carsten Ringler Anzeige |
02.04.24 · Business Wire (engl.) |
Werte aus der Branche Rohstoffe
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,5650 | +14,00 | |
| 0,5340 | +12,90 | |
| 337,00 | +12,33 | |
| 0,8947 | +11,85 | |
| 0,8000 | +11,03 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 183,20 | -19,30 | |
| 1,1367 | -22,67 | |
| 12,000 | -25,00 | |
| 8,3600 | -39,81 | |
| 46,60 | -97,97 |
Beitrag zu dieser Diskussion schreiben
FeedbackWas ist hier los?!?
Was ist hier los?!
Antwort auf Beitrag Nr.: 66.063.136 von Justnew am 14.12.20 19:31:35Erstmal soll's wieder unter 3,90CAD fallen um das GAP zu schliessen.
Bisschen Korrektur wird's auch geben.
Der Rest steht in den Sternen.
Bisschen Korrektur wird's auch geben.
Der Rest steht in den Sternen.
meint ihr 5€ sind hier drin kurzzeitig?
Provides Clinical Development Update on 18-MC
Based on positive pre-IND meeting with U.S. Food and Drug Administration (FDA), MindMed is now prepared to open an Investigational New Drug (IND) in August 2021 with a Phase 2b clinical trial for LSD assisted therapy in anxiety
MindMed continues dose escalation of 18-MC in Phase I SAD/MAD; Meeting confirmed with FDA
NEW YORK, Dec. 14, 2020 /CNW/ -- MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy for an anxiety disorder.
MindMed Project Lucy
MindMed Project Lucy
The successful completion of this engagement with the FDA is an important milestone for the company and provides regulatory clarity and confidence as MindMed advances its lead clinical development program in the U.S. MindMed intends to open the IND with the FDA in August 2021, with a Phase 2b clinical trial evaluating experiential doses of LSD in an anxiety disorder.
MindMed Co-Founder & Co-CEO J.R. Rahn said "The FDA is one of the most impactful organizations for regulated drug development globally. We look forward to working through the FDA pathway on psychedelic assisted therapies in strict compliance with their proven drug development guidelines and commencing our Phase 2b trial for Project Lucy in 2021."
18-MC (Project Layla) Phase 1 Clinical Development Update
Preliminary data has been analyzed for MindMed's addiction treatment program evaluating the ibogaine derivative 18-MC, which the company has named Project Layla. The preliminary data from the Phase 1 Multiple Ascending Dose (MAD) and Single Ascending Dose (SAD) study has shown that the drug is safe and well tolerated at the doses tested to date, and no Serious Adverse Events (SAEs) have been reported.
Based on the excellent safety profile observed to date, MindMed's clinical team and 18-MC's Medical Director, Dr. Judy Ashworth, have decided to continue dose escalation in the study to gather higher dosing data. Once that additional data has been reviewed, MindMed will directly thereafter initiate the Phase 2a proof of concept study. A meeting with the FDA has been confirmed to continue discussions regarding the 18-MC clinical development plan.
Based on positive pre-IND meeting with U.S. Food and Drug Administration (FDA), MindMed is now prepared to open an Investigational New Drug (IND) in August 2021 with a Phase 2b clinical trial for LSD assisted therapy in anxiety
MindMed continues dose escalation of 18-MC in Phase I SAD/MAD; Meeting confirmed with FDA
NEW YORK, Dec. 14, 2020 /CNW/ -- MindMed (NEO: MMED, OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy for an anxiety disorder.
MindMed Project Lucy
MindMed Project Lucy
The successful completion of this engagement with the FDA is an important milestone for the company and provides regulatory clarity and confidence as MindMed advances its lead clinical development program in the U.S. MindMed intends to open the IND with the FDA in August 2021, with a Phase 2b clinical trial evaluating experiential doses of LSD in an anxiety disorder.
MindMed Co-Founder & Co-CEO J.R. Rahn said "The FDA is one of the most impactful organizations for regulated drug development globally. We look forward to working through the FDA pathway on psychedelic assisted therapies in strict compliance with their proven drug development guidelines and commencing our Phase 2b trial for Project Lucy in 2021."
18-MC (Project Layla) Phase 1 Clinical Development Update
Preliminary data has been analyzed for MindMed's addiction treatment program evaluating the ibogaine derivative 18-MC, which the company has named Project Layla. The preliminary data from the Phase 1 Multiple Ascending Dose (MAD) and Single Ascending Dose (SAD) study has shown that the drug is safe and well tolerated at the doses tested to date, and no Serious Adverse Events (SAEs) have been reported.
Based on the excellent safety profile observed to date, MindMed's clinical team and 18-MC's Medical Director, Dr. Judy Ashworth, have decided to continue dose escalation in the study to gather higher dosing data. Once that additional data has been reviewed, MindMed will directly thereafter initiate the Phase 2a proof of concept study. A meeting with the FDA has been confirmed to continue discussions regarding the 18-MC clinical development plan.
Charttechnisch sind wir im Aufwärtstrend, korrigieren werden wir aber bestimmt irgendwann.
Keine Ahnung was an News ansteht, die letzten Neuigkeiten sehe ich nicht als Grund dafür.
Eine Glaskugel hab ich leider auch keine.
Mal sehen was am Nachmittag passiert.
Keine Ahnung was an News ansteht, die letzten Neuigkeiten sehe ich nicht als Grund dafür.
Eine Glaskugel hab ich leider auch keine.
Mal sehen was am Nachmittag passiert.
Trading Spotlight
Was sagt ihr geht es noch Mal tiefer?
Mind Medicine Mindmed Inc. : MindMed erhält von Gesundheitsbehörden in Schweiz und Niederlanden Zulassung für Protokolldesign zur Bewertung von LSD-Mikrodosierung bei Erwachsenen mit ADHS im Rahmen einer klinischen Phase-IIa-Studie
https://ch.marketscreener.com/kurs/aktie/MIND-MEDICINE-MINDM…
https://ch.marketscreener.com/kurs/aktie/MIND-MEDICINE-MINDM…
Schön zu sehen, dass Mindmed seine Adresse in ein Büro in New York, NY, geändert hat.
Antwort auf Beitrag Nr.: 66.047.954 von sektor64 am 13.12.20 10:39:44Meines Wissens braucht das Unternehmen min. eine MK von15Mio, min. 1.000.000 Shares in freier Hand, etc
Google einfach mal. Wirst fündig.
Canaccord prüft gerade ein Listening.
Google einfach mal. Wirst fündig.
Canaccord prüft gerade ein Listening.
Weiss jemand wann ein Listing an der Nasdaq möglich ist oder was es dazu braucht?
Durchsuchen
MindMed als Marktführer einer neuen Multimilliarden-Anlageklasse
